NEW YORK (GenomeWeb News) - Galapagos has received a €500,000 ($665,000) grant from a European research consortium that aims to use genomics, proteomics, and functional genomics to help in the regeneration of injured kidneys, the company said today.
The grant was awarded by the Proligen consortium to Galapagos’ BioFocus DPI division, which identifies and validates drug targets and compound libraries using adenoviral agents.
The Proligen consortium is funded over three years with €2.5 million by the European Union’s Sixth Framework Program. Other Proligen members include universities and companies from Spain, Switzerland, the Netherlands, and Germany.
Under the terms of the deal, BioFocus will use its adenoviral libraries and cellular assay knowledge to target starting points for treatment of kidney injuries.